Trial Profile
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Diabetic nephropathies; Renal impairment
- Focus Pharmacodynamics
- Sponsors Biogen; Reata Pharmaceuticals
- 26 Oct 2023 Planned End Date changed from 1 Oct 2013 to 30 Nov 2012.
- 23 Oct 2012 Planned end date changed from 1 Dec 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 23 Oct 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.